Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

PD1 and PDL1 Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Incyte Corporation, Bristol-Myers Squibb, Novartis, Bayer, Beigene, Merck, AbbVie, and Others Expected to Propel Market

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

09 May, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In addition, the high incidence of diseases and participation of key players will emerge in favor of the change in the PD-1 and PD-L1 inhibitors market dynamics. 

LAS VEGAS, May 9, 2023 /PRNewswire/ -- DelveInsight's PD1 and PDL1 Inhibitors Competitive Landscape report delivers an in-depth understanding of the PD1 and PDL1 inhibitors and the PD1 and PDL1 inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the PD1 and PDL1 Inhibitors Market Report

  • DelveInsight analysis shows that the PD1 and PDL1 inhibitors market is expected to grow positively due to several underline factors during the study period (2019–2032).
  • Leading PD1 and PDL1 inhibitors companies such as Incyte Corporation, TG Therapeutics, Novartis, Beigene, Buzzard Pharmaceuticals, Bristol-Myers Squibb, OncoC4, Inc., Phanes Therapeutics, Compass Therapeutics, Merck Sharp & Dohme LLC, 4D Pharma plc, Chugai Pharma, Bayer, AbbVie, Kartos Therapeutics, Inc., NeoImmuneTech, Dr. Reddys Laboratories, SA, BioNTech SE, Istari Oncology, Inc., Jounce Therapeutics, Inc., NovoCure Ltd., and others are developing novel PD1 and PDL1 inhibitors that can be available in the PD1 and PDL1 inhibitors market in the coming years.
  • Some key PD1 and PDL1 inhibitors include Retifanlimab, TG-1501 (cosibelimab), PDR001 (spartalizumab), BGB-A317 (tislelizumab), Isunakinra, Nivolumab, ONC-392, PT199, CTX-471, Pembrolizumab, MRx0518, RO5126766, BAY3375968, ABBV-CLS-484, KRT-232, NT-I7, E7777, BNT116, Lerapolturev, JTX-8064, NovoTTF-200T, FAZ053, and others.
  • Several PD1 and PDL1 inhibitors are awaiting approval, while some PD1 and PDL1 inhibitors are in the advanced stages of development. 
  • In July 2022, Bristol-Myers Squibb announced that Part A of the Phase III CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as an adjuvant treatment for patients with localized renal cell carcinoma (RCC) who have undergone full or partial removal of the kidney and who are at moderate or high risk of relapse, did not meet the primary endpoint of disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR).
  • In June 2022, the US FDA accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA for the adjuvant treatment of patients with stage IB (≥4 centimeters), II or IIIA non-small cell lung cancer (NSCLC) following complete surgical resection. The sBLA is based on data from the pivotal Phase III KEYNOTE-091 trial data, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS.
  • In June 2022, adjuvant treatment with KEYTRUDA (pembrolizumab) demonstrated statistically significant & clinically meaningful improvement in distant metastasis-free survival in patients with resected Stage IIB or IIC Melanoma in Phase III KEYNOTE-716 trial.
  • In March 2022, the US FDA approved KEYTRUDA as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation

Discover which PD1 and PDL1 inhibitors are expected to grab the major PD1 and PDL1 inhibitors market share @ PD1 and PDL1 Inhibitors Market Report

PD1 and PDL1 Inhibitors Overview

PD-1 is a checkpoint protein found in T cells, which are immune cells. It generally functions as an "off switch" that prevents T cells from attacking other cells in the body. This occurs when it binds to PD-L1, a protein found on some normal (and malignant) cells. When PD-1 attaches to PD-L1, it effectively signals the T cell to ignore the other cell. Some cancer cells have a high level of PD-L1, which allows them to hide from an immune response. Monoclonal antibodies targeting PD-1 or PD-L1 can inhibit this binding and increase the immune response against cancer cells. These medications have shown tremendous promise in the treatment of some malignancies. OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), BAVENCIO (avelumab), IMFINZI (durvalumab), LIBTAYO (cemiplimab), and JEMPERLI (dostarlimab) are some examples of authorized drugs that target PD-1/PD-L1. These drugs have been proven to be successful in treating multiple types of cancer, and new cancer types are being added as more research demonstrates their efficacy.

PD1 and PDL1 Inhibitors Market Insights

PD-1/PD-L1 blockage is a breakthrough in cancer immunotherapy that has been tested in preclinical and clinical trials for a wide range of cancers, including melanoma, Hodgkin's lymphoma, breast cancer, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma. Anti-programmed cell death 1 (PD-1) immune checkpoint drugs are actively redefining the therapy approach for many of the related disorders. The anti-PD-1 drugs Nivolumab (OPDIVO, Bristol-Myers Squibb) and Pembrolizumab (KEYTRUDA, Merck Sharp and Dohme Corporation) have recently been approved by the US Food and Drug Administration for the treatment of patients with advanced NSCLC who have progressed on or after first-line therapy. 

Nivolumab and Pembrolizumab have already demonstrated highly promising performance in clinical trials, with ORRs of around 20% in unselected and severely pre-treated NSCLC patients. Cemiplimab-rwlc (LIBTAYO, Regeneron Pharmaceuticals Inc.) has also been approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation. Nivolumab and Pembrolizumab have also been approved by the European Medicines Agency (EMA) for the same indication. Furthermore, both the US and European regulators recommended pembrolizumab as first-line therapy for advanced NSCLCs.

Moreover, cancer immunotherapy has improved significantly in recent years, with some receiving FDA approval for cancer treatment. With this advancement, PD-1 blocking treatments can now be utilized in combination with other anti-tumor therapies in addition to acting as monotherapy. Pembrolizumab was also paired with chemotherapy in clinical research for the treatment of non-small cell lung cancer (NSCLC). Furthermore, combination therapy that combines PD-1/PD-L1 blocking medicines has demonstrated high potency and efficacy. Combination therapies may become standard cancer treatment in the future.

To know more about PD1 and PDL1 inhibitors, visit @ PD1 and PDL1 Inhibitors Analysis

Key PD1 and PDL1 Inhibitors Drugs and Companies

  • Retifanlimab: Incyte Corporation
  • TG-1501 (cosibelimab): TG Therapeutics
  • PDR001 (spartalizumab): Novartis
  • BGB-A317 (tislelizumab): Beigene
  • Isunakinra: Buzzard Pharmaceuticals
  • Nivolumab: Bristol-Myers Squibb
  • ONC-392: OncoC4, Inc.
  • PT199: Phanes Therapeutics
  • CTX-471: Compass Therapeutics
  • Pembrolizumab: Merck Sharp & Dohme LLC
  • MRx0518: 4D Pharma plc
  • RO5126766: Chugai Pharma
  • BAY3375968: Bayer
  • ABBV-CLS-484: AbbVie
  • KRT-232: Kartos Therapeutics, Inc.
  • NT-I7: NeoImmuneTech
  • E7777: Dr. Reddys Laboratories, SA
  • BNT116: BioNTech SE
  • Lerapolturev: Istari Oncology, Inc.
  • JTX-8064: Jounce Therapeutics, Inc.
  • NovoTTF-200T: NovoCure Ltd.
  • FAZ053: Novartis

Learn more about the FDA-approved PD1 and PDL1 inhibitors @ Approved PD1 and PDL1 Inhibitors 

PD1 and PDL1 Inhibitors Market Dynamics

The dynamics of the PD1 and PDL1 inhibitors market are predicted to change in the coming years. Premium-priced targeted therapies with improved clinical profiles and the extension of therapy in the first-line setting are projected to fuel the growth of the PD1 and PDL1 inhibitors market. According to current research, the development of innovative therapies targeting specific mutations is predicted to dominate the forthcoming PD1 and PDL1 inhibitors market, implying that the PD-1 market will also expand. Furthermore, the PD1 and PDL1 inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the PD1 and PDL1 inhibitors market in the 7MM.

However, several factors are impeding the growth of the PD1 and PDL1 inhibitors market. The development of therapies for specific mutations limits the patient group eligible for drugs that target the entire population. In addition, the high costs connected with research activities, pricing, and reimbursement issues faced by high-priced medications. Furthermore, the anticipated entry of generic or biosimilar versions of blockbuster medications such as Keytuda, Opdivo, and others will reduce market sales and thus cause a dip in the PD1 and PDL1 inhibitors market growth. 

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Base Year

2019

Key PD1 and PDL1 Inhibitors Companies

Incyte Corporation, TG Therapeutics, Novartis, Beigene, Buzzard Pharmaceuticals, Bristol-Myers Squibb, OncoC4, Inc., Phanes Therapeutics, Compass Therapeutics, Merck Sharp & Dohme LLC, 4D Pharma plc, Chugai Pharma, Bayer, AbbVie, Kartos Therapeutics, Inc., NeoImmuneTech, Dr. Reddys Laboratories, SA, BioNTech SE, Istari Oncology, Inc., Jounce Therapeutics, Inc., NovoCure Ltd., and others

Key PD1 and PDL1 Inhibitors Therapies

Retifanlimab, TG-1501 (cosibelimab), PDR001 (spartalizumab), BGB-A317 (tislelizumab), Isunakinra, Nivolumab, ONC-392, PT199, CTX-471, Pembrolizumab, MRx0518, RO5126766, BAY3375968, ABBV-CLS-484, KRT-232, NT-I7, E7777, BNT116, Lerapolturev, JTX-8064, NovoTTF-200T, FAZ053, and others

Scope of the PD1 and PDL1 Inhibitors Market Report

  • Therapeutic Assessment: Current Marketed and Emerging PD1 and PDL1 Inhibitors 
  • PD1 and PDL1 Inhibitors Market Dynamics: Attribute Analysis of Emerging PD1 and PDL1 Inhibitors 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, PD1 and PDL1 Inhibitors Market Access and Reimbursement

Discover more about PD1 and PDL1 inhibitors in clinical development @ PD1 and PDL1 Inhibitors in Clinical Trials

Table of Contents

1.

PD1 and PDL1 Inhibitors Market Key Insights

2.

PD1 and PDL1 Inhibitors Market Report Introduction

3.

PD1 and PDL1 Inhibitors Market Overview at a Glance

4.

PD1 and PDL1 Inhibitors Market Executive Summary

5.

Disease Background and Overview

6.

PD1 and PDL1 Inhibitors Marketed Drugs

7.

PD1 and PDL1 Inhibitors Emerging Drugs

8.

Seven Major PD1 and PDL1 Inhibitors Market Analysis

9.

PD1 and PDL1 Inhibitors Market Outlook

10.

Potential of Current and Emerging Therapies

11.

KOL Views

12.

PD1 and PDL1 Inhibitors Market Drivers

13.

PD1 and PDL1 Inhibitors Market Barriers

14.

Unmet Needs

15.

SWOT Analysis

16.

Appendix

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

Related Reports

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.

PD-1 Resistant Head and Neck Cancer Market

PD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 resistant head and neck cancer companies, including AstraZeneca, Innate Pharma, Rakuten Medical, Boehringer Ingelheim, Alkermes, among others.

PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Merck, Sanofi, Bristol Myers Squibb, among others.

PD-1 Non-Small Cell Lung Cancer Market

PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 non-small cell lung cancer companies, including Wuhan University, Dalian University, MSD, Sichuan University, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 
Shruti Thakur  
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.